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Abstract
Objective: Herpes simplex virus type 2 (HSV-2) suppression has been shown to reduce HIV-1 disease progression in non-
pregnant women and men, but effects on pregnant and postpartum women have not been described.
Methods: We analyzed data from a cohort of Kenyan women participating in a randomized clinical trial of HSV-2
suppression. Pregnant HIV-1-seropositive, HSV-2-seropositive women who were not eligible for antiretroviral therapy (WHO
stage 1–2, CD4.250 cells/ml) were randomized to either 500 mg valacyclovir or placebo twice daily from 34 weeks gestation
through 12 months postpartum. Women received zidovudine and single-dose nevirapine for prevention of mother-to-child
HIV-1 transmission. HIV-1 progression markers, including CD4 count and plasma HIV-1 RNA levels, were measured serially.
Multivariate linear regression was used to compare progression markers between study arms.
Results: Of 148 women randomized, 136 (92%) completed 12 months of postpartum follow-up. While adjusted mean CD4
count at 12 months (565 cells/ml placebo arm, 638 cells/ml valacyclovir arm) increased from antenatal levels in both arms, the
mean CD4 count increase was 73 cells/ml higher in the valacyclovir arm than placebo arm (p=0.03). Mean increase in CD4
count was 154 cells/ml in the valacyclovir arm, almost double the increase of 78 cells/ml in the placebo arm. At 12 months,
adjusted HIV-1 RNA levels in the placebo arm increased by 0.66 log10 copies/ml from baseline, and increased by only 0.21
log10 copies/ml in the valacyclovir arm (0.40 log10 copies/ml difference, p=0.001).
Conclusion: Women randomized to valacyclovir suppressive therapy during pregnancy and postpartum had greater
increases in CD4 counts and smaller increases in plasma HIV-1 RNA levels than women in the placebo arm. Valacyclovir
suppression during pregnancy and breastfeeding may improve outcomes and delay antiretroviral therapy for HIV-1/HSV-
2 co-infected women.
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Introduction
Addressing herpes simplex virus type 2 (HSV-2) co-infection
may be a pathway to improving health of HIV-1 infected mothers.
More than 80% of HIV-1-seropositive women in sub-Saharan
Africa are co-infected with HSV-2 [1]. HSV-2 co-infection has
been associated with higher plasma HIV-1 RNA loads, and higher
HIV-1 viral set points if HSV-2 infection precedes HIV-1
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HSV-2 co-infected persons have consistently shown reductions in
HIV-1 plasma RNA levels, but these trials have excluded pregnant
women [4,5,6,7,8,9,10,11]. Recent randomized clinical trials of
acyclovir for herpes suppression in co-infected persons have
demonstrated 16–25% reductions in HIV-1 disease progression
endpoints over 2 years of follow-up [12,13]. Progression endpoints
for both studies included CD4 thresholds and evidence of clinical
disease progression including non-traumatic death and/or ART
initiation.
Valacyclovir is now available in generic form, providing higher
levels of acyclovir with a simpler regimen, improving adherence
and potentially increasing effects on HIV-1 progression. We
analyzed data from a randomized, double-blind, placebo-con-
trolled trial to determine whether valacyclovir reduces maternal
disease progression, using CD4 count as the primary marker,
when taken in late pregnancy and for 12 months postpartum.
Methods
Study Design
Participants were part of a randomized, double-blind, placebo-
controlled trial of valacyclovir suppressive therapy of 500 mg twice
daily in pregnant HIV-1/HSV-2 co-infected women from 34
weeks gestation to 12 months postpartum, as previously described
[14]. The original study was powered to detect at least a 0.50 log10
copies/ml difference in plasma HIV-1 RNA levels. The study was
approved by Kenyatta National Hospital Ethical Review Com-
mittee and the University of Washington Institutional Review
Board, and registered at ClinicalTrials.gov under Identifier NCT
00530777. All participants provided written informed consent.
Participants
Women presenting to public clinics in Nairobi, Kenya for
antenatal care between April 2008 and June 2009 were recruited if
they resided in Nairobi and were HIV-1-seropositive by rapid tests
according to local protocols. Pregnant women with HIV-1 who
were $18 years of age had HIV-1 confirmed by enzyme-linked
immunosorbant assay (ELISA), HSV-2 antibodies, and CD4
count. HIV-1/HSV-2-seropositive women with CD4 counts .250
cells/ml and World Health Organization (WHO) clinical stage 1–2
were eligible.
Study participants received routine antenatal care and preven-
tion of mother-to-child HIV-1 transmission (PMTCT) according
to Kenya national guidelines: oral zidovudine (ZDV) 300 mg twice
daily from 28 weeks gestation, oral ZDV at onset of labor and
every 3 hours until delivery, single-dose nevirapine 200 mg at
onset of labor, and ZDV or ZDV/lamivudine ‘‘tail’’ for 7 days
postpartum. Baseline CD4 counts were measured prior to
initiation of PMTCT regimens.
Enrollment took place at 34 weeks to allow completion of
laboratory tests to determine eligibility. All women in the study
received the following free of charge: antenatal and delivery care,
co-trimoxazole prophylaxis, multivitamins in pregnancy, family
planning, and prescribed outpatient medications.
Study Procedures
WHO stage was determined at enrollment. Women were seen
at 38 weeks gestation, within 48 hours of delivery, at 2, 6, 10, and
14 weeks postpartum, and at 6, 9, and 12 months postpartum.
Antenatal study visits focused on obstetric care; postpartum visits
included a physical exam and assessment of WHO stage. If women
became eligible for antiretroviral therapy (ART) after enrollment,
they were referred for treatment but continued to participate in
the study. Counseling to promote adherence to study drug was
done regularly. Women returned all unused pills to the study each
month and at study termination. Adherence was measured by self-
report of number of pills missed and by pill count at follow-up
visits.
Laboratory Methods
HIV-1 serostatus was confirmed by ELISA (Vironostika HIV
Uni-Form II, bioMe ´rieux, France) and HSV-2 serostatus was
determined using ELISA (HerpeSelect, Focus Technologies,
Cypress, CA) with a cutoff optical density (OD) $3.5 [15]. Tests
were repeated if OD was between 1.1 and 3.4; women were
eligible if the repeat assay was positive. CD4 counts were
performed in Nairobi using flow cytometry (FACSCalibur or
FACSCount, BectonDickinson, Franklin Lakes, NJ). HIV-1 RNA
assays were conducted using a transcription-mediated amplifica-
tion method validated for HIV-1 subtypes prevalent in Kenya
(Gen-Probe Inc, San Diego, CA) [16]. HIV-1 RNA levels below
the lower limit of detection (150 copies/ml) were recoded as half
the value of the lower limit of detection.
Study Outcomes
The primary outcomes of this nested study were CD4 counts
and log10 plasma HIV-1 RNA levels compared between partic-
ipants in the two study arms. Secondary outcomes included
maternal morbidity, initiation of ART, mortality events and
changes in WHO stage. Other study results, including effects of
valacyclovir on breast milk HIV-1, genital HIV-1, and genital
HSV-2 have been reported elsewhere [14]. A data safety
monitoring board regularly evaluated adverse events; there were
no criteria for stopping the study early other than safety.
Statistical Methods
Analyses were conducted using Stata Version 10.0 (College
Station, TX). All participants with a postpartum visit were
included in this intention-to-treat analysis. Adequacy of random-
ization was assessed by chi-square and Fisher’s exact tests for
categorical variables and Wilcoxon rank-sum tests for continuous
variables comparing baseline values in both arms. Primary
endpoints of CD4 counts and log10 HIV-1 plasma RNA levels
at 6 months and 12 months were assessed using 2-sided t-tests and
multivariate linear regression, controlling for baseline values. Cox
proportional hazards regression was used to compare progression
events in both arms. Adherence to study drug was measured by
monthly pill counts and monthly self-report. Pill counts were
totaled over the duration of the study and adherence was
calculated as follows: (total pills dispensed – total pills missed)/
total pills dispensed.
Results
Study Population
Women in both study arms had comparable baseline health
status (Table 1). Most women lived in poverty in the urban slum
neighborhoods surrounding the clinic. At enrollment, 85% of
women in the placebo arm and 93% of women in the valacyclovir
arm were WHO stage 1. Tuberculosis treatment was reported by
4% of women and 6% had prior herpes zoster. Participants in
both study arms had similar baseline median CD4 counts and
log10 HIV-1 plasma RNA levels. Almost all women (93% placebo,
100% valacyclovir) had started ZDV for PMTCT before study
enrollment.
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Retention was high: 146 (99%) participants had at least one
postpartum visit, and 136 women (92%) were followed for 12
months. Adherence to study drug was high among study
participants, and was sustained over 12 months postpartum. By
pill count, overall adherence averaged 85% (84% placebo, 85%
valacyclovir).
CD4 Counts
Mean CD4 counts improved from baseline in both randomi-
zation arms (Table 2). Of the 116 participants with CD4 count
results available at 6 months postpartum, mean CD4 increased
from 484 cells/ml to 631 cells/ml in the valacyclovir arm and 487
cells/ml to 612 cells/ml in the placebo arm (P=0.72). At 12
months, with 136 (93%) participants measured, we observed a
higher mean CD4 in the valacyclovir arm than in the placebo arm
(638 cells/ml vs. 565 cells/ml, respectively; P=0.09). After
adjusting for baseline CD4, the 12 month mean increase in
CD4 counts was 73 cells/ml higher in the valacyclovir arm (P
=0.03). Mean increase in CD4 count was 154 cells/ml in the
valacyclovir arm, almost double the increase of 78 cells/ml in the
placebo arm (Figure 1).
HIV-1 RNA Levels
Mean plasma HIV-1 RNA levels were lowest in pregnancy
(valacyclovir arm: 3.89 log10 copies/ml, placebo arm: 3.87 log10
copies/ml), when women were taking ZDV for PMTCT.
Previously published data from this trial modeled plasma HIV-1
RNA from 6 weeks to 12 months postpartum and described an
average 0.51 log copies/ml reduction in HIV-1 plasma RNA levels
between study arms during that period [14]. In the present
analysis, we report all antenatal, 6 month and 12 month plasma
HIV-1 RNA data. During the postpartum period, HIV-1 RNA
levels rebounded in both study arms after completion of maternal
antiretrovirals (ARVs), but increases in HIV-1 RNA levels were
smaller in the valacyclovir arm. At 6 months postpartum, after
adjusting for baseline levels, plasma HIV-1 RNA levels were 0.42
log10 copies/ml lower in the valacyclovir arm than in the placebo
arm (Table 2). At 12 months postpartum, adjusted plasma HIV-1
RNA levels were 0.40 log10 copies/ml lower in the valacyclovir
arm than in the placebo arm; mean HIV-1 RNA increased by 0.21
log10 copies/ml in the valacyclovir arm, and increased by three
times more, 0.66 log10 copies/ml, in the placebo arm (P=0.001).
Maternal Morbidity, Mortality, and Obstetric Outcomes
Despite provision of free care to study participants, there were
multiple poor maternal outcomes. Overall, 3 women (2%) died
during the study (2 placebo, 1 valacyclovir) and 7 (5%) were
hospitalized (5 placebo, 2 valacyclovir). Poor birth outcome with
fetal demise occurred in 3 women (2 placebo, 1 valacyclovir) who
had third-trimester stillbirths. Other morbidities included tuber-
culosis (6 women), diarrhea/colitis (26 women), malaria (20
women) and pneumonia (7 women). Overall, 6 women progressed
to WHO Stage 3 or 4 during the study, 3 in each arm. Sixteen
women (7 on placebo, 9 on valacyclovir) had a progression event
(death, CD4,250 cells/ml, WHO stage 3–4; or opportunistic
infection). Cox proportional hazards regression models assessing
time to disease progression events revealed no significant
Table 1. Baseline Maternal Health Characteristics, by Treatment Arm.
Baseline Health Characteristic Placebo n=73 Valacyclovir n=73
Median (IQR)
or n (%)
Median (IQR)
or n (%) P value*
Age (years) 25 (22–29) 25 (22–30) 0.82
Prior STI 18 (25%) 20 (27%) 0.71
Prior syphilis 4 (5%) 4 (5%) 1.00
Prior GUD 13 (18%) 10 (13%) 0.5
Prior TB 3 (4%) 3 (4%) 1.00
Prior herpes zoster 5 (7%) 4 (6%) 0.73
On ARVs for PMTCT 68 (93%) 73 (100%) 0.02
WHO Stage 1 62 (85%) 68 (93%) 0.11
CD4 count (cells/mL) 481 (340–598) 452 (351–560) 0.78
Log10 HIV-1 plasma RNA level (copies/ml) 3.84 (3.43–.45) 3.99 (3.30–4.41) 0.86
No symptoms this pregnancy 44 (60%) 47 (64%) 0.61
Symptoms this pregnancy
Fever 16 (22%) 18 (25%) 0.70
Malaria 12 (16%) 12 (16%) 1.00
Diarrhea 11 (15%) 15 (21%) 0.39
Cough 22 (30%) 27 (37%) 0.38
Weight loss 3 (4%) 9 (12%) 0.13
Itchy rash 4 (5%) 4 (5%) 1.00
Thrush 4 (5%) 4 (5%) 1.00
IQR = Interquartile range. USD = US Dollars. STI = sexually transmitted infection. GUD = genital ulcer disease. ARVs = antiretrovirals. TB = tuberculosis. PMTCT =
prevention of mother-to-child transmission of HIV-1. *P value calculated using the Wilcoxon rank-sum test for continuous variables and chi-squared and Fisher’s exact
test for categorical variables.
doi:10.1371/journal.pone.0038622.t001
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powered for these outcomes and events were few. There were no
serious adverse events related to use of valacyclovir.
Discussion
Our study of daily valacyclovir during late pregnancy and
postpartum showed a significant increase in CD4 counts among
women in the valacyclovir arm at 12 months postpartum. CD4 is
the most reliable marker of HIV-1 disease progression and
morbidity in pregnant and postpartum African women [17].
Although all women in this study received short-course maternal
ARVs for PMTCT, the rise in maternal CD4 count in the
valacyclovir arm was sustained months after maternal ARVs for
PMTCT had been discontinued. This improvement in CD4 is
plausible since we concurrently observed less increase in plasma
HIV-1 RNA among women in the valacyclovir arm, modeled over
the entire study period. Given that asymptomatic African patients
with HIV-1 lose an estimated 30–60 CD4 cells/ml per year
[18,19,20], improved CD4 counts of the magnitude observed in
this study could translate into improved outcomes and delayed
need for ART for postpartum women.
This is the first randomized trial reporting results of valacyclovir
on HIV-1 disease progression specifically among pregnant women
in Africa. Other studies in African non-pregnant HIV-1 infected
populations have noted benefits of acyclovir, including the
landmark trial by Lingappa et al, noting a 16% reduction in
HIV-1 disease progression with acyclovir therapy [12], and a
randomized controlled trial in Uganda of daily acyclovir among
HIV-1/HSV-2 seropositive adults with CD4 counts 300–400
Table 2. Effect of Valacyclovir on Mean CD4 Count and Log10 Plasma HIV-1 RNA Level.
Placebo Valacyclovir
Difference,
adjusted*
n Mean (SD) Mean (SD) Mean 95% CI P
CD4 count (cells/ml)
Enrollment 146 487 (174) 484 (179) 23 261, 55 0.92
6 months postpartum 116 612 (232) 631 (309) 17 258, 93 0.72
12 months postpartum 136 565 (206) 638 (292) 73 6, 140 0.03
Log10 plasma HIV-1 RNA (copies/ml)
Enrollment 146 3.87 (0.83) 3.89 (0.95) 20.01 20.18, 0.17 0.95
6 months postpartum 136 4.40 (0.81) 3.98 (1.05) 20.42 20.65, 20.2 ,0.001
12 months postpartum 136 4.53 (0.81) 4.10 (1.07) 20.40 20.63, 20.17 0.001
SD = standard deviation.
*method used: Multivariate linear regression models control for baseline plasma HIV-1 RNA levels for plasma HIV-1 RNA models, and baseline CD4 for CD4 models.
doi:10.1371/journal.pone.0038622.t002
Figure 1. Change in CD4 count over time in participants on valacyclovir compared to placebo. Mean CD4 counts were compared at each
timepoint by multivariate linear regression, adjusting for baseline values. Baseline CD4 counts were measured during pregnancy, prior to initiation of
PMTCT antiretroviral short-course therapy.
doi:10.1371/journal.pone.0038622.g001
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24 months [13]. Mugwanya et al published data showing that
higher doses of valacyclovir may have more potential to impact
HIV-1 disease [21]. Modeling studies have predicted similar
declines in HIV-1 disease progression with herpes suppressive
therapy [22,23]. A recent cost-effectiveness analysis indicates that
HSV-2 suppression to delay ART could be cost-effective in South
Africa; HSV-2 suppression could potentially be more cost-effective
in other African countries where labor costs are lower [24].
Further, long-term studies of acyclovir in HIV-1/HSV-2 co-
infected adults showed no evidence of significant HIV-1 resistance
mutations [25], and no evolution of HSV-2 resistance to acyclovir
[26], even when adherence was sub-optimal, indicating that
prolonged use of anti-herpes medication has few downsides.
Consistent with prior studies of daily acyclovir and valacyclovir,
we found high adherence (86%) during the peri- and postpartum
periods. Women successfully adhered to twice daily valacyclovir
despite extreme poverty, motherhood, and even when concealing
both HIV status and study participation. We believe that
community health workers were instrumental in supporting
adherence in our study, and conclude that widespread use of this
therapy should be possible in most African settings, especially if
accompanied by support for adherence.
The randomized design of this study proved helpful in
comparing CD4 counts in pregnant and postpartum women,
which fluctuate due to hemodilution of pregnancy and use of
ARVs for PMTCT. Other strengths of this study include its
extended duration of follow-up, excellent retention, and imple-
mentation within existing PMTCT programs. The small number
of women in our study and the relatively brief follow-up time
limited our ability to comment on disease progression events.
Although valacyclovir is now a generic medication, it is not widely
available in resource-limited settings, and continues to be relatively
expensive.
What would be the role of valacyclovir, given the current push
for elimination of PMTCT? Efforts to scale-up HIV treatment
include increasing recognition of the benefits, both reduced infant
HIV transmission and improved maternal outcomes, when
pregnant women are started on ART or prophylaxis as early as
possible [27], especially mothers who need ART for their own
health. WHO guidelines recommend that, in addition to providing
ART to all pregnant women with CD4#350 cells/ml, countries
choose either short-course maternal ZDV during pregnancy and
infant prophylaxis during breastfeeding (‘‘Option A’’) or maternal
ART during pregnancy and breastfeeding (‘‘Option B’’) as
preferred interventions to eliminate MTCT [28]. Some countries,
such as Malawi, are adopting ‘‘Option B-Plus’’ and placing
women on lifelong ART [29], but there are ongoing concerns
about retaining women in care who initiate ART solely for
PMTCT [30,31]. Thousands of women will continue to receive
only ZDV prophylaxis under ‘‘Option A;’’ this trial shows that
valacyclovir could benefit these women, especially since short-
course regimens in pregnancy will continue to have a place in
PMTCT programming for the foreseeable future.
In conclusion, pregnant and postpartum women randomized to
500 mg of valacyclovir twice daily had greater improvements in
CD4 counts and lower postpartum maternal HIV-1 RNA levels
when compared to women randomized to placebo. HIV-1 infected
women and their children in Africa continue to face serious health
consequences and excess mortality due to a lack of comprehensive
and timely HIV-1 care and prevention. There is an urgent need to
improve maternal CD4 counts and reduce maternal HIV-1
disease progression to promote maternal and child survival. The
promising CD4 data from this trial indicate that valacyclovir may
be a tool to reduce progression events in women. Further studies
are needed to determine whether peripartum valacyclovir therapy
may be useful to improve maternal outcomes in settings where
access to ART is limited and HSV-2 co-infection is prevalent.
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